Updates of CSCO guidelines for colorectal cancer version 2025.
作者信息
Lu Demin, Dong Caixia, Wang Kailai, Ye Chenyang, Chen Liubo, Yuan Ying, Hu Hanguang
机构信息
Department of Medical Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang Province, China), the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Zhejiang Provincial Clinical Research Center for Cancer, Hangzhou 310009, China.
出版信息
Chin J Cancer Res. 2025 Jun 30;37(3):297-302. doi: 10.21147/j.issn.1000-9604.2025.03.01.
Abstract
摘要
相似文献
1
Updates of CSCO guidelines for colorectal cancer version 2025.
Chin J Cancer Res. 2025 Jun 30;37(3):297-302. doi: 10.21147/j.issn.1000-9604.2025.03.01.
2
Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018.
Chin J Cancer Res. 2019 Jun;31(3):423-425. doi: 10.21147/j.issn.1000-9604.2019.03.03.
3
Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019.
Chin J Cancer Res. 2020 Jun;32(3):403-407. doi: 10.21147/j.issn.1000-9604.2020.03.11.
4
Application of Case-Based Learning Combined with PDCA in the Training of Grassroot Surgeons for the Updates in the CSCO Guidelines for the Diagnosis and Treatment of Breast (2023).
Niger J Clin Pract. 2025 May 1;28(5):666-671. doi: 10.4103/njcp.njcp_161_24. Epub 2025 Jun 4.
5
CSCO guidelines for colorectal cancer version 2023: Updates and insights.
Chin J Cancer Res. 2023 Jun 30;35(3):233-238. doi: 10.21147/j.issn.1000-9604.2023.03.02.
6
CSCO guidelines for colorectal cancer version 2024: Updates and discussions.
Chin J Cancer Res. 2024 Jun 30;36(3):233-239. doi: 10.21147/j.issn.1000-9604.2024.03.01.
7
CSCO guidelines for colorectal cancer version 2022: Updates and discussions.
Chin J Cancer Res. 2022 Apr 30;34(2):67-70. doi: 10.21147/j.issn.1000-9604.2022.02.01.
8
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update.
Cancer Commun (Lond). 2025 Mar;45(3):332-379. doi: 10.1002/cac2.12639. Epub 2024 Dec 31.
9
Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022.
Transl Breast Cancer Res. 2022 Apr 30;3:13. doi: 10.21037/tbcr-22-21. eCollection 2022.
10
Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020.
Chin J Cancer Res. 2021 Jun 30;33(3):302-307. doi: 10.21147/j.issn.1000-9604.2021.03.02.
本文引用的文献
1
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
Lancet. 2025 Feb 1;405(10476):383-395. doi: 10.1016/S0140-6736(24)02848-4. Epub 2025 Jan 25.
2
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141.
3
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response.
Nat Rev Clin Oncol. 2024 Dec;21(12):839-851. doi: 10.1038/s41571-024-00943-6. Epub 2024 Sep 24.
4
Cancer incidence and mortality in China, 2022.
J Natl Cancer Cent. 2024 Feb 2;4(1):47-53. doi: 10.1016/j.jncc.2024.01.006. eCollection 2024 Mar.
5
CSCO guidelines for colorectal cancer version 2024: Updates and discussions.
Chin J Cancer Res. 2024 Jun 30;36(3):233-239. doi: 10.21147/j.issn.1000-9604.2024.03.01.
6
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial.
Ann Oncol. 2024 Oct;35(10):882-891. doi: 10.1016/j.annonc.2024.06.015. Epub 2024 Jul 2.
7
Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH).
J Clin Oncol. 2024 Oct;42(28):3308-3318. doi: 10.1200/JCO.23.02261. Epub 2024 Jul 1.
8
Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.
Lancet Oncol. 2024 Jul;25(7):843-852. doi: 10.1016/S1470-2045(24)00203-1. Epub 2024 Jun 6.
9
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
10
Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer.
JAMA Surg. 2024 May 1;159(5):529-537. doi: 10.1001/jamasurg.2023.7996.
Zotero 插件